Pfizer reported third-quarter results that beat analyst estimates and raised its full-year outlook, citing demand for newly launched and acquired products. The company now expects full-year revenue of $62 billion to $64 billion, up from a previous range of $60.5 billion to $62.5 billion. Pfizer cited its "strong year-to-date performance" as the reason for the raise.
The company also named Cecile Guegan as chief financial officer. She had served as interim CFO since August, after Dave Denton left to become CFO of Nike. Guegan has held various finance leadership roles at Pfizer over the last two decades.
Pfizer raised its full-year adjusted earnings guidance to between $2.95 and $3.05 per share, from $2.80 to $3 per share. That figure includes a one-time $650 million charge, or 10 cents per share, tied to the company's licensing and collaboration agreement with Chinese cancer drugmaker Innovent Biologics.
Third-quarter revenue was $16.58 billion, roughly flat from a year earlier. Eliquis, the blood thinner, brought in $2.52 billion, up 25% and above the $2.40 billion analysts expected, according to StreetAccount. Padcev, a targeted cancer drug, posted $720 million, compared with analyst expectations of $658 million.
Pfizer's newly launched and acquired products contributed $3.8 billion, growing 32% on an operational basis, Guegan said on the earnings call. Covid products also beat estimates. The Covid vaccine generated $808 million, against expectations of $770.4 million, and the antiviral Paxlovid booked $449 million, against $394.1 million expected.
CEO Albert Bourla told CNBC that Covid product revenue was "very low" this quarter and year, but called it "positive news for us." Pfizer reaffirmed its Covid product outlook of roughly $4 billion for the year and expects most Covid shot sales in the fourth quarter.
Pfizer reported net income of $3.24 billion, or 56 cents per share, for the quarter, down from $3.54 billion, or 62 cents per share, a year earlier. Excluding certain items, earnings per share were 87 cents.